For people who have gastric intestinal metaplasia (GIM) You may be able to join this study if all of the following apply. You: have had an endoscopy in the past and tissue samples (biopsies) showed ...

Tissue epithelia maintain their lineage identity under normal conditions but occasionally undergo ‘reprogramming’ into another lineage—a phenomenon known as metaplasia. Notable examples include ...

Intestinal Metaplasia at the Esophagogastric Junction and Gastric Cardia. A columnar-lined esophagus does not appear to pose a risk of malignancy unless there is intestinal metaplasia.

BACKGROUND AND AIMS Gastric metaplasia is frequently seen in biopsies of the duodenal cap, particularly when inflamed or ulcerated. In its initial manifestation small patches of gastric foveolar cells ...

Abstract: Metaplasia, growth of normal tissue in an abnormal location, is a precursor lesion of gastric cancer (GC). Despite the huge impact of the Operative Link on Gastritis Assessment based on ...

Gastric Intestinal Metaplasia (GIM) is believed to be a precancerous condition, a process often driven by chronic inflammation by H. pylori infection, bile acid exposure, or environmental factors ...

The study of gastric cancer and its precursors, such as metaplasia, remains critical in addressing one of the leading causes of cancer‐related mortality worldwide.

Memorial Sloan Kettering Cancer Center researchers have identified a metabolic switch that determines whether intestinal stem ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer. Excellent standards of ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...